WO2009125415A1 - Forme amorphe de citrate de sildénafil - Google Patents

Forme amorphe de citrate de sildénafil Download PDF

Info

Publication number
WO2009125415A1
WO2009125415A1 PCT/IN2008/000226 IN2008000226W WO2009125415A1 WO 2009125415 A1 WO2009125415 A1 WO 2009125415A1 IN 2008000226 W IN2008000226 W IN 2008000226W WO 2009125415 A1 WO2009125415 A1 WO 2009125415A1
Authority
WO
WIPO (PCT)
Prior art keywords
sildenafil citrate
amorphous form
amorphous
sildenafil
citrate
Prior art date
Application number
PCT/IN2008/000226
Other languages
English (en)
Inventor
Bandi Parthasaradhi Reddy
Kura Rathnakar Reddy
Rapolu Raji Reddy
Dasari Muralidhara Reddy
Valivarthi Vsv Prasad
Original Assignee
Hetero Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Research Foundation filed Critical Hetero Research Foundation
Priority to PCT/IN2008/000226 priority Critical patent/WO2009125415A1/fr
Publication of WO2009125415A1 publication Critical patent/WO2009125415A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the invention relates to a novel amorphous form of sildenafil citrate, to a process for the preparation thereof and to a composition comprising thereof.
  • Sildenafil citrate is known by the chemical name 1-[[3-(4,7-Dihydro-1- methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl] -4-methylpiperazine citrate.
  • Sildenafil citrate is an antihypertensive agent having a treatment of male erectile dysfunction.
  • Sildenafil citrate is represented by the following structure:
  • Sildenafil and its citrate salt may be prepared using the procedures described in Eur. Pat. No. 00463756 and WO 2005/067936 A2.
  • U.S. pat. App. No. 2004/0235857 A1 discloses crystalline forms of sildenafil citrate Anhydrous Form, Hydrated Form and Hydrated forms of sildenafil hemicitrate.
  • sildenafil citrate in substantially amorphous form has higher bioavailability than when in crystalline form and that moreover the amorphous form of Sildenafil citrate has adequate chemical stability upon storage and therefore can be used in pharmaceutical formulation.
  • the object of present invention is to provide a novel amorphous form of sildenafil citrate (herein after referred to as amorphous sildenafil citrate), process for preparation thereof and a pharmaceutical composition containing it.
  • amorphous sildenafil citrate a novel amorphous form of sildenafil citrate
  • amorphous sildenafil citrate substantially amorphous form.
  • the amorphous form of sildenafil citrate present invention is characterized by powder x-ray diffraction pattern as shown in fig.1 and FTIR spectrum as shown in fig.2.
  • the amorphous sildenafil citrate according to the invention is prepared by a process which constitutes a further feature of the present invention and which comprises recovering sildenafil citrate from an aqueous solution of sildenafil citrate thereof under conditions whereby a substantially amorphous product is obtained.
  • Substantial amorphous sildenafil citrate refers to amorphous form having less than 5% crystallinity as measured by X-RD techniques.
  • Techniques which are employed to recover amorphous sildenafil citrate from the solution thereof include those wherein water is removed from an aqueous solution of sildenafil citrate and the product deposited. Methods involving the use of these procedures include spray drying and vacuum drying.
  • a pharmaceutical composition comprising amorphous sildenafil citrate and a pharmaceutically acceptable excipient.
  • Preferable pharmaceutical composition of amorphous sildenafil citrate is a solid oral dosage form, comprising amorphous sildenafil citrate.
  • Figure 1 is X-ray powder diffraction spectrum of amorphous sildenafil citrate.
  • Figure 2 is FTIR spectrum of amorphous sildenafil citrate.
  • X-ray powder diffraction spectrum was measured on a bruker axs D8 advance X-ray powder diffractometer having a copper-K ⁇ radiation. Approximately 1gm of sample was gently flattered on a sample holder and scanned from 2 to 50 degrees two-theta, at 0.03 degrees to theta per step and a step of 0.5 seconds. The sample was simply placed on the sample holder. The sample was rotated at 30 rpm at a voltage 40 KV and current 35 mA.
  • Crystalline sildenafil citrate (5 gm) is dissolved in water (800 ml). The solution is subjected to vacuum drying at 80 0 C for 10 hours to give quantative yield of amorphous sildenafil citrate.
  • Crystalline sildenafil citrate (5 gm) is dissolved in water (800 ml) and heated to 50 - 6O 0 C and the solution is subjected to spray drying at 80 0 C for 30 minutes to give quantative yield of amorphous sildenafil citrate.
  • Spray dryer conditions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur une nouvelle forme amorphe de citrate de sildénafil, sur un procédé pour la fabrication de celle-ci et sur une composition la contenant.
PCT/IN2008/000226 2008-04-07 2008-04-07 Forme amorphe de citrate de sildénafil WO2009125415A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2008/000226 WO2009125415A1 (fr) 2008-04-07 2008-04-07 Forme amorphe de citrate de sildénafil

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2008/000226 WO2009125415A1 (fr) 2008-04-07 2008-04-07 Forme amorphe de citrate de sildénafil

Publications (1)

Publication Number Publication Date
WO2009125415A1 true WO2009125415A1 (fr) 2009-10-15

Family

ID=41161591

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000226 WO2009125415A1 (fr) 2008-04-07 2008-04-07 Forme amorphe de citrate de sildénafil

Country Status (1)

Country Link
WO (1) WO2009125415A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107722019A (zh) * 2015-07-23 2018-02-23 青岛华之草医药科技有限公司 一种治疗男性勃起功能障碍的枸橼酸西地那非化合物
US9968609B2 (en) 2014-03-19 2018-05-15 Vigorous Solutions Ltd. Sildenafil solutions and methods of making and using same
CN109867677A (zh) * 2017-12-04 2019-06-11 广州白云山医药集团股份有限公司白云山化学制药厂 一种回收制备西地那非的方法
CN112618508A (zh) * 2021-01-15 2021-04-09 遂成药业股份有限公司 一种稳定无定型的枸橼酸西地那非片及其生产工艺

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235857A1 (en) * 2003-02-11 2004-11-25 Pfizer Inc Crystalline therapeutic agent
WO2005067936A2 (fr) * 2004-01-05 2005-07-28 Teva Pharmaceutical Industries Ltd. Procedes de fabrication de sildenafil base et de son sel citrate
WO2005115330A2 (fr) * 2004-05-28 2005-12-08 Pfizer Products Inc. Compositions pharmaceutiques aux performances accrues
EP1779852A2 (fr) * 2004-01-05 2007-05-02 Teva Pharmaceutical Industries Ltd. Procédés de production d'une base de sildenafil et de sel de citrate

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235857A1 (en) * 2003-02-11 2004-11-25 Pfizer Inc Crystalline therapeutic agent
WO2005067936A2 (fr) * 2004-01-05 2005-07-28 Teva Pharmaceutical Industries Ltd. Procedes de fabrication de sildenafil base et de son sel citrate
EP1779852A2 (fr) * 2004-01-05 2007-05-02 Teva Pharmaceutical Industries Ltd. Procédés de production d'une base de sildenafil et de sel de citrate
WO2005115330A2 (fr) * 2004-05-28 2005-12-08 Pfizer Products Inc. Compositions pharmaceutiques aux performances accrues

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9968609B2 (en) 2014-03-19 2018-05-15 Vigorous Solutions Ltd. Sildenafil solutions and methods of making and using same
US10211534B2 (en) 2014-03-19 2019-02-19 Vigorous Solutions Ltd. Sildenafil solutions and methods of making and using same
CN107722019A (zh) * 2015-07-23 2018-02-23 青岛华之草医药科技有限公司 一种治疗男性勃起功能障碍的枸橼酸西地那非化合物
CN107722018A (zh) * 2015-07-23 2018-02-23 青岛华之草医药科技有限公司 一种治疗男性勃起功能障碍的枸橼酸西地那非化合物
CN107722020A (zh) * 2015-07-23 2018-02-23 青岛华之草医药科技有限公司 一种治疗男性勃起功能障碍的枸橼酸西地那非化合物
CN107827895A (zh) * 2015-07-23 2018-03-23 青岛华之草医药科技有限公司 一种制备治疗男性勃起功能障碍的枸橼酸西地那非化合物的方法
CN107880047A (zh) * 2015-07-23 2018-04-06 青岛华之草医药科技有限公司 一种枸橼酸西地那非化合物
CN107880048A (zh) * 2015-07-23 2018-04-06 青岛华之草医药科技有限公司 一种枸橼酸西地那非化合物
CN107903270A (zh) * 2015-07-23 2018-04-13 青岛华之草医药科技有限公司 一种治疗男性勃起功能障碍的枸橼酸西地那非化合物
CN109867677A (zh) * 2017-12-04 2019-06-11 广州白云山医药集团股份有限公司白云山化学制药厂 一种回收制备西地那非的方法
CN112618508A (zh) * 2021-01-15 2021-04-09 遂成药业股份有限公司 一种稳定无定型的枸橼酸西地那非片及其生产工艺

Similar Documents

Publication Publication Date Title
CA2717326C (fr) Preparation de lenalidomide
EP2535342B1 (fr) Sel de dérivé hétérocyclique condensé et cristal de celui-ci
US10766895B2 (en) Preparation methods for palbociclib free base crystal form A and crystal form B
US20040010151A1 (en) Lansoprazole polymorphs and processes for preparation thereof
JP2003530321A (ja) Ｎ−［４−［２−（２−アミノ−４，７−ジヒドロ−４−オキソ−３Ｈ−ピロロ［２，３−ｄ］ピリミジン−５−イル）エチル］ベンゾイル］−Ｌ−グルタミン酸の新規結晶形およびその製造方法
US20090181990A1 (en) Stable amorphous form of pemetrexed disodium
WO2007013086A1 (fr) Nouveaux polymorphes de tenofovir disoproxil fumarate
TWI831848B (zh) 用於口服投予之包含胺基嘧啶衍生物或其鹽的醫藥組成物
RU2613555C2 (ru) Моногидратный кристалл калиевой соли фимасартана, способ его получения и содержащая его фармакологическая композиция
CN112105616B (zh) 药学化合物、其盐类、其制剂和其制备和使用方法
US20100081809A1 (en) Amorphous valganciclovir hydrochloride
JP2015134774A (ja) 医薬化合物の結晶化
WO2009125415A1 (fr) Forme amorphe de citrate de sildénafil
JP2021523880A (ja) ジヒドロピリミジン化合物の固体形態及びその調製方法及びその使用
WO2010028105A2 (fr) Disodium de pemetrexed amorphe
WO2013107236A1 (fr) Forme cristalline de sel (6s)-5-méthyltétrahydrofolate et procédé pour sa préparation
AU2018205995A1 (en) Solid forms of [(1S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-te trahydrofuran-2-yl]propyl] acetate
US20170056424A1 (en) Solid forms of tenofovir
WO2014009970A2 (fr) Dispersion solide de linagliptine
KR20180006441A (ko) 요산 수송체 억제제의 나트륨 염 및 이의 결정성 형태
CA3098274A1 (fr) Formes polymorphes de bictegravir et son sel de sodium
EP3031808B1 (fr) Sel d'idelalisib
WO2016147206A1 (fr) Procédé pour la préparation d'idélalisib amorphe et son mélange préliminaire
WO2017130219A1 (fr) Dispersion solide amorphe de palbociclib
WO2018078383A1 (fr) Composition pharmaceutique comprenant du selexipag amorphe

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08763719

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08763719

Country of ref document: EP

Kind code of ref document: A1